End-of-day quote
Shanghai S.E.
23:00:00 14/07/2024 BST
5-day change
1st Jan Change
23.76
CNY
-0.34%
-2.06%
+38.87%
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
October 27, 2020 at 08:08 am
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 1,749.409 million compared to CNY 1,691.027 million a year ago. Operating income was CNY 314.759 million compared to CNY 309.653 million a year ago. Net income was CNY 269.569 million compared to CNY 261.818 million a year ago. Basic earnings per share from continuing operations was CNY 0.475 compared to CNY 0.449 a year ago.
Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug
05-13
MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-25
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
04-25
CI
Henan Lingrui Pharma Registers Chewable Asthma Drug in China
04-19
MT
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
27/10/23
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
09/08/23
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
25/04/23
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
25/04/23
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
27/10/22
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
05/08/22
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
25/04/22
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
25/04/22
CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million.
30/01/22
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
03/01/22
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
27/10/21
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
07/10/21
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
30/08/21
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
02/07/21
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
28/04/21
CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.
01/04/21
CI
Henan Lingrui Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
01/02/21
CI
Henan Lingrui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
31/01/21
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
27/10/20
CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020
17/08/20
CI
Henan Lingrui Pharmaceutical Co., Ltd. Announces Cash Dividend for 2019, Payable on June 19, 2020
11/06/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
More about the company
Last Close Price
23.76
CNY
Average target price
30.5
CNY
Spread / Average Target
+28.37%
Consensus
1st Jan change
Capi.
+38.87% 1.85B +13.97% 4.99B -32.08% 3.61B -1.63% 3.1B -24.62% 2.64B -9.82% 2.32B +38.84% 1.43B -15.47% 1.39B +40.95% 1.37B -26.18% 1.3B
Alternative Medicine
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1